A practical guide to the evaluation and treatment of male lower urinary tract symptoms in the primary care setting

International Journal of Clinical Practice

Volumn 61, Issue 9, 2007, Pages 1535-1546

  Rosenberg, M T ^a,f,g   Staskin, D R ^b   Kaplan, S A ^b   MacDiarmid, S A ^c   Newman, D K ^d   Ohl, D A ^e,g  

^a Foote Health System   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c Bladder Control and Pelvic Pain Center   (United States)

^d HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f University of Michigan ^*  (United States)

^g Urologic Health Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DOXAZOSIN; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN; TOLTERODINE; TROSPIUM CHLORIDE;

ALGORITHM; BEHAVIOR THERAPY; CONSTIPATION; DECISION MAKING; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; EVALUATION; HISTORY OF MEDICINE; HUMAN; INCIDENCE; INTERVENTION STUDY; LOWER URINARY TRACT SYMPTOM; MEDICAL PRACTICE; MICTURITION; MONOTHERAPY; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PHYTOTHERAPY; POSTVOID RESIDUAL URINE VOLUME; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; REFRACTORY PERIOD; REVIEW; SOCIAL ASPECT; STORAGE; XEROSTOMIA;

EID: 34547788182     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2007.01491.x     Document Type: Review

References (53)

1. Hyman MJ, Groutz A, Blaivas JG. Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001 166 : 550 3.
2. Van Venrooij GE, Van Melick HH, Eckhardt MD et al. Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol 2002 168 : 605 9.
3. Kaplan SA, Ikeguchi EF, Santarosa RP et al. Etiology of voiding dysfunction in men less than 50 years of age. Urology 1996 47 : 836 9.
4. Fawzy A, Fontenot C, Guthrie R et al. Practice patterns among primary care physicians in benign prostatic hyperplasia and prostate cancer. Fam Med 1997 29 : 321 5.
5. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 61 : 37 49.
6. Dennis L, Griffiths K, Khoury S et al. Recommendations of the International Scientific Committee: the evaluation and treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction. In : Denis L, Griffiths K, Khoury S, Cockett ATK, McConnell J, Chatelain C, Murphy C, Yoshida O. eds. Proceedings of the Fourth International Consultation on Benign Prostatic Hyperplasia. London : Health Publications, Ltd., 1998 : 669 84.
7. Lee C, Cockett A, Cussenot K et al. Regulation of prostate growth. In : Chatelain C, Denis L, Foo KT, Khoury S, McConnell J. eds. Proceedings of the Fifth International Consultation of Benign Prostatic Hyperplasia, Chapter 3. London : Health Publications, Ltd., 2001 : 79 106.
8. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 187 : 167 78.
9. Ouslander JG. Management of overactive bladder. N Engl J Med 2004 350 : 786 99.
10. Wein AJ. Pathophysiology and categorization of voiding dysfunction. In : Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell-Walsh Urology, 9th edn. Philadelphia, PA : Saunders Elsevier, 2007 : 1973 85.
11. Chapple CR, Artibani W, Cardozo LD et al. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int 2005 95 : 335 40.
12. Jaffe WI, Te AE. Overactive bladder in the male patient: epidemiology, etiology, evaluation, and treatment. Curr Urol Rep 2005 6 : 410 8.
13. Stewart WF, Van Rooyen JB, Cundiff GW et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003 20 : 327 36.
14. Berry SJ, Coffee DS, Walsh PC et al. The development of human benign prostatic hyperplasia with age. J Urol 1984 132 : 474 9.
15. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005 173 : 1256 61.
16. Rosenberg M. The sad, misunderstood prostate: understanding perceptions and reality. Int J Clin Pract 2006 60 : 1148 9.
17. Jacobsen SJ, Girman CJ, Guess HA et al. New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 1995 155 : 477 81.
18. O'Conor RM, Johannesson M, Hass SL et al. Urge incontinence. Quality of life and patients' valuation of symptom reduction. Pharmacoeconomics 1998 14 : 531 9.
19. Bruskewitz RC. Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol 2003 5 : 72 80.
20. Nickel JC. BPH: costs and treatment outcomes. Am J Manag Care 2006 12 (Suppl. 5 S141 8.
21. McGhan WF. Cost effectiveness and quality of life considerations in the treatment of patients with overactive bladder. Am J Manag Care 2001 7 (Suppl. 2 S62 75.
22. Haidinger G, Temml C, Schatzl G et al. Risk factors for lower urinary tract symptoms in elderly men. For the Prostate Study Group of the Austrian Society of Urology. Eur Urol 2000 37 : 413 20.
23. Gades NM, Jacobson DJ, Girman CJ et al. Prevalence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int 2005 95 : 549 53.
24. Speakman MJ, Kirby RS, Joyce A et al. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004 93 : 985 90.
25. van Kerrebroeck P, Abrams P, Chaikin D et al. for the Standardisation Sub-committee of the International Continence Society. The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002 21 : 179 83.
26. Roehrborn CG, McConnell JD, Barry MJ. Guidelines on the Management of Benign Prostatic Hyperplasia. Linthicum, MD : American Urological Association, Education and Research, Inc., 2003.
27. Barry MJ, Fowler FJ Jr., O'Leary MP et al. and the Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992 148 : 1549 57.
28. Naslaund MJ, Costa FJ, Miner MM. Managing enlarged prostate in primary care. Int J Clin Pract 2006 60 : 1609 15.
29. Suzuki S, Platz EA, Kawachi I et al. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am J Clin Nutr 2002 75 : 689 97.
30. Rohrmann S, Giovannucci E, Willett WC et al. Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am J Clin Nutr 2007 85 : 523 9.
31. Miner M, Rosenberg MT, Perelman MA. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function. Clin Ther 2006 28 : 13 25.
32. Lepor H, Williford WO, Barry MJ et al. for the Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. The impact of medical therapy on bother due to symptoms, quality of life and global outcome, and factors predicting response. Veteran Affairs Cooperative Studies Benign Hyperplasia Study Group. J Urol 1998 160 : 1358 67.
33. Lowe FC. Role of the newer alpha, -adrenergic receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 2004 26 : 1701 13.
34. Kirby RS. Doxazosin in benign prostatic hyperplasia. Effects on blood pressure and urinary flow in normotensive and hypertensive men. Urology 1995 46 : 182 6.
35. Kirby RS. Terazosin in benign prostatic hyperplasia. Effects on blood pressure in normotensive and hypertensive men. Br J Urol 1998 82 : 373 9.
36. Kaplan SA. Update on the American Urological Association guidelines for the treatment of benign prostatic hyperplasia. Rev Urol 2006 8 (Suppl. 4 S10 7.
37. McConnell JD, Roehrborn CG, Bautista OM et al. for the Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 349 : 2387 98.
38. Abrams P, Kaplan S, De Koning Gans HJ et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006 175 : 999 1004.
39. McNeill SA, Hargreave TB, Geffriaud-Ricouard C et al. Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: pooled analysis of eleven controlled studies alfuzosin. Urology 2001 57 : 459 65.
40. Kolman C, Girman CJ, Jacobsen SJ et al. Distribution of post-void residual urine in randomly selected men. J Urol 1999 161 : 122 7.
41. Goode PS, Locher JL, Bryant RL et al. Measurement of postvoid residual urine with portable transabdominal bladder ultrasound scanner and urethral catheterization. Int Urogynecol J Pelvic Floor Dysfunct 2000 11 : 296 300.
42. Coombes GM, Millard RJ. The accuracy of portable ultrasound scanning in the measurement of residual urine volume. J Urol 1994 152 (6 part 1 2083 5.
43. Byun SS, Kim HH, Lee E et al. Accuracy of bladder volume determinations by ultrasonography: are they accurate over entire bladder volume range? Urology 2003 62 : 656 60.
44. Ockrim JL, Laniado ME, Patel A et al. A probability based system for combining simple office parameters as a predictor of bladder outflow obstruction. J Urol 2001 166 : 2221 5.
45. Abrams P. Urodynamics, 3rd edn. London, England : Springer, 2005.
46. Burgio KL, Locher JL, Goode PS. Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatric Soc 2000 48 : 370 4.
47. Andersson K-E. Antimuscarinics for treatment of overactive bladder. Lancet Neurol 2004 3 : 46 53.
48. Steers W, Corcos J, Foote J et al. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist. BJU Int 2005 95 : 580 6.
49. Chapple CR, Martinez-Garcia R, Selvaggi L et al. for the STAR study group. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005 48 : 464 70.
50. Blake-James BT, Rashidian A, Ikeda Y et al. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 2006 99 : 85 96.
51. Lee JY, Kim HW, Lee SJ et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and overactive bladder. BJU Int 2004 94 : 817 20.
52. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005 174 : 2273 6.
53. Kaplan S, Naslund M. Public, patient, and professional attitudes towards the diagnosis and treatment of enlarged prostate: a landmark national US survey. Int J Clin Pract 2006 60 : 1157 65.